Matthew P. Goetz, MD, on Advanced Breast Cancer: Expert Perspectives
2016 San Antonio Breast Cancer SymposiumMatthew P. Goetz, MD, of the Mayo Clinic, reviews progress made during the past year on treatment of advanced disease.
Matthew P. Goetz, MD, of the Mayo Clinic, reviews progress made during the past year on treatment of advanced disease.
Aleix Prat, MD, PhD, of the University of Barcelona, discusses study findings on intrinsic subtype as a predictor of pathologic complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer (Abstract S3-03).
Diana M. Eccles, MD, of the University of Southampton, discusses findings from a study of sporadic and hereditary breast cancer and whether BRCA status affects outcome in young breast cancer patients (Abstract S2-03).
Eric P. Winer, MD, of the Dana-Farber Cancer Institute, summarizes his McGuire lecture on the past and future of breast cancer treatment.
Sabine Linn, MD, PhD, and Sonja Vliek, MD, both of the Netherlands Cancer Institute, discuss study findings on adjuvant ibandronate in postmenopausal women with early breast cancer (Abstract S6-02).
Ruth O’Regan, MD, of the University of Wisconsin, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss study findings on the prognostic associations of TILs in metastatic HER2-positive breast cancer (Abstract S1-04).